Currently out of the existing stock ratings of Andy Chen, 1 are a SELL (4.76%), 15 are a BUY (71.43%), 5 are a HOLD (23.81%).

Andy Chen

Work Performance Price Targets & Ratings Chart

Analyst Andy Chen, currently employed at WOLFE, carries an average stock price target met ratio of 58.33% that have a potential upside of 37.9% achieved within 213 days.

Andy Chen’s has documented 40 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 16-Jul-2026.

Wall Street Analyst Andy Chen

Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 9/24/2025. The price target of $25 was fulfilled within 15 days with a profit of $7.24 (40.77%) receiving and performance score of 27.18.

Average potential price target upside

of $77.04 (21.64%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $28.53 (60.57%) on KYMR (KYMERA THERAPEUTICS).
of $10.16 (102.96%) on NTLA (INTELLIA THERAPEUTICS).

IMVT Immunovant INSM Insmed KYMR Kymera Therapeutics MDGL Madrigal Pharmaceuticals MLTX MoonLake Immunotherapeutics NTLA Intellia Therapeutics VERA Vera Therapeutics VRTX Vertex Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Samantha Semenkow (CITI)